{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:43:28Z","timestamp":1771047808088,"version":"3.50.1"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1002139","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T21:47:47Z","timestamp":1314913667000},"page":"e1002139","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":114,"title":["A Computational Approach to Finding Novel Targets for Existing Drugs"],"prefix":"10.1371","volume":"7","author":[{"given":"Yvonne Y.","family":"Li","sequence":"first","affiliation":[]},{"given":"Jianghong","family":"An","sequence":"additional","affiliation":[]},{"given":"Steven J. M.","family":"Jones","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2011,9,1]]},"reference":[{"key":"ref1","article-title":"How to improve R&D productivity: The pharmaceutical industry's grand challenge Nature Reviews Drug Discovery.","author":"SM Paul","year":"2010"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/nbt1007-1073","article-title":"Drug output slows in 2006.","volume":"25","author":"S Lawrence","year":"2007","journal-title":"Nat Biotechnol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs.","volume":"3","author":"TT Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","article-title":"Imatinib as a paradigm of targeted therapies.","volume":"91","author":"B Druker","year":"2004","journal-title":"Adv Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity.","volume":"26","author":"MW Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"ref6","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","author":"RD Morin","year":"2010","journal-title":"Nat Genet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2 in granulosa-cell tumors of the ovary.","volume":"360","author":"SP Shah","year":"2009","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e1000423","DOI":"10.1371\/journal.pcbi.1000423","article-title":"Drug discovery using chemical systems biology: Repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis.","volume":"5","author":"SL Kinnings","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs.","volume":"462","author":"MJ Keiser","year":"2009","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1158140","article-title":"Drug target identification using side-effect similarity.","volume":"321","author":"M Campillos","year":"2008","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1126\/science.1096361","article-title":"The many roles of computation in drug discovery.","volume":"303","author":"WL Jorgensen","year":"2004","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1367-5931(00)00217-9","article-title":"High-throughput docking for lead generation.","volume":"5","author":"R Abagyan","year":"2001","journal-title":"Curr Opin Chem Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcc.540150503","article-title":"ICM\u2014A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation.","volume":"15","author":"R Abagyan","year":"1994","journal-title":"J Comput Chem"},{"key":"ref14","article-title":"ICM manual.","author":"R Abagyan","year":"2007"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.bmcl.2005.12.067","article-title":"In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.","volume":"16","author":"CN Cavasotto","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10822-009-9266-3","article-title":"Effects of protein conformation in docking: Improved pose prediction through protein pocket adaptation.","volume":"23","author":"AN Jain","year":"2009","journal-title":"J Comput Aided Mol Des"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd1177","article-title":"p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases.","volume":"2","author":"S Kumar","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/ci8002254","article-title":"Protein-ligand docking against non-native protein conformers.","volume":"48","author":"ML Verdonk","year":"2008","journal-title":"J Chem Inf Model"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1021\/jm0608356","article-title":"Benchmarking sets for molecular docking.","volume":"49","author":"N Huang","year":"2006","journal-title":"J Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.","volume":"110","author":"U Rix","year":"2007","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1021\/bi100070r","article-title":"Analysis of imatinib and sorafenib binding to p38alpha compared with c-abl and b-raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.","volume":"49","author":"HV Namboodiri","year":"2010","journal-title":"Biochemistry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/0008-5472.379.65.2","article-title":"Cellular targets of gefitinib.","volume":"65","author":"D Brehmer","year":"2005","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib.","volume":"1804","author":"PW Manley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: To be or not to be?","volume":"10","author":"K Ghoreschi","year":"2009","journal-title":"Nat Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-007-0592-9","article-title":"Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.","volume":"17","author":"K Koyama","year":"2007","journal-title":"Mod Rheumatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/RHU.0b013e318188b1ce","article-title":"Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.","volume":"14","author":"KK Eklund","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0b013e3181b0d352","article-title":"Resolution of rheumatoid arthritis symptoms with imatinib mesylate.","volume":"15","author":"MR Vernon","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"ref28","article-title":"Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.","author":"N Akashi","year":"2010","journal-title":"Mod Rheumatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors.","volume":"351","author":"SP Davies","year":"2000","journal-title":"Biochem J"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.str.2004.01.005","article-title":"Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1.","volume":"12","author":"D Komander","year":"2004","journal-title":"Structure"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1073\/pnas.0708800104","article-title":"A systematic interaction map of validated kinase inhibitors with Ser\/Thr kinases.","volume":"104","author":"O Fedorov","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/00912700222011193","article-title":"Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women.","volume":"42","author":"MM Cotreau","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.","volume":"138","author":"GG Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14728210902771334","article-title":"Emerging drugs for psoriasis.","volume":"14","author":"L Naldi","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1389557033488204","article-title":"Vitamin D receptor as a drug discovery target.","volume":"3","author":"KV Pinette","year":"2003","journal-title":"Mini Rev Med Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential.","volume":"54","author":"U Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"ref37","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.","volume":"60","author":"JM Wood","year":"2000","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl.","volume":"7","author":"E Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"27045","DOI":"10.1016\/S0021-9258(19)61478-X","article-title":"Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein.","volume":"275","author":"GK Balendiran","year":"2000","journal-title":"J Biol Chem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.STR.0000149620.74770.2e","article-title":"Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection.","volume":"36","author":"L Belayev","year":"2005","journal-title":"Stroke"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors.","volume":"23","author":"MA Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.","volume":"25","author":"M Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/1535-7163.MCT-08-0826","article-title":"Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors.","volume":"7","author":"P Ross-Macdonald","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.copbio.2009.08.003","article-title":"Docking and chemoinformatic screens for new ligands and targets.","volume":"20","author":"P Kolb","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1016\/j.bmcl.2008.09.046","article-title":"Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. part 2: Identification of active compounds.","volume":"18","author":"M Sabio","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: A comprehensive resource for in silico drug discovery and exploration.","volume":"34","author":"DS Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/nar\/gkg095","article-title":"The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003.","volume":"31","author":"B Boeckmann","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1074\/mcp.M400159-MCP200","article-title":"Pocketome via comprehensive identification and classification of ligand binding envelopes.","volume":"4","author":"J An","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/ci010097o","article-title":"SLIPPER-2001 \u2013 software for predicting molecular properties on the basis of physicochemical descriptors and structural similarity.","volume":"42","author":"OA Raevsky","year":"2002","journal-title":"J Chem Inf Comput Sci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks.","volume":"13","author":"P Shannon","year":"2003","journal-title":"Genome Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"D142","DOI":"10.1093\/nar\/gkp846","article-title":"The universal protein resource (UniProt) in 2010.","volume":"38","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3348\/kjr.2003.4.2.109","article-title":"Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: Its feasibility compared with transjugular intrahepatic portosystemic shunt.","volume":"4","author":"YH Choi","year":"2003","journal-title":"Korean J Radiol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0960-9822(02)00972-7","article-title":"High-resolution structure of the pleckstrin homology domain of protein kinase b\/akt bound to phosphatidylinositol (3,4,5)-trisphosphate.","volume":"12","author":"CC Thomas","year":"2002","journal-title":"Curr Biol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"30303","DOI":"10.1074\/jbc.271.48.30303","article-title":"Mutation of the pleckstrin homology domain of bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity.","volume":"271","author":"M Fukuda","year":"1996","journal-title":"J Biol Chem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1107\/S0907444904020645","article-title":"Structure of human erythrocyte NADH-cytochrome b5 reductase.","volume":"60","author":"S Bando","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/138161208784246171","article-title":"Methylenetetrahydrofolate reductase (MTHFR): A novel target for cancer therapy.","volume":"14","author":"J Stankova","year":"2008","journal-title":"Curr Pharm Des"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"13538","DOI":"10.1021\/bi011482+","article-title":"Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase.","volume":"40","author":"SE Greasley","year":"2001","journal-title":"Biochemistry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors.","volume":"23","author":"MA Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1021\/bi100070r","article-title":"Analysis of imatinib and sorafenib binding to p38alpha compared with c-abl and b-raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.","volume":"49","author":"HV Namboodiri","year":"2010","journal-title":"Biochemistry"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2003.10.030","article-title":"Drospirenone, a progestogen with antimineralocorticoid properties: A short review.","volume":"217","author":"W Oelkers","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1074\/jbc.270.41.23975","article-title":"Differential activation of peroxisome proliferator-activated receptors by eicosanoids.","volume":"270","author":"K Yu","year":"1995","journal-title":"J Biol Chem"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.atherosclerosissup.2006.01.007","article-title":"Diabetes: Assessing the pipeline.","author":"H Lebovitz","year":"2006","journal-title":"Atheroscler"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/jmbi.2000.4032","article-title":"Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.","volume":"302","author":"BP Klaholz","year":"2000","journal-title":"J Mol Biol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0006-2952(00)00269-0","article-title":"Effect of receptor-selective retinoids on growth and differentiation pathways in mouse melanoma cells.","volume":"59","author":"SH Desai","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"22441","DOI":"10.1074\/jbc.271.37.22441","article-title":"4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors.","volume":"271","author":"AN Fanjul","year":"1996","journal-title":"J Biol Chem"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1074\/mcp.M400003-MCP200","article-title":"Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain.","volume":"3","author":"J Lengqvist","year":"2004","journal-title":"Mol Cell Proteomics"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T22:01:57Z","timestamp":1712786517000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002139"}},"subtitle":[],"editor":[{"given":"Philip E.","family":"Bourne","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1002139","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}